Evidence map›Paper›PMID 37408007›Full record

ArticleJournal of nanobiotechnology2023

Biomimetic hypoxia-triggered RNAi nanomedicine for synergistically mediating chemo/radiotherapy of glioblastoma.

Zhen Wang, Xiang-Long Tang, Meng-Jie Zhao, Yi-Ding Zhang, Yong Xiao, Yu-Yang Liu, Chun-Fa Qian, Yan-Dong Xie, Yong Liu, Yuan-Jie Zou and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Zhen Wang *Department of Neurosurgery, The Affiliated Brain Hospital With Nanjing Medical University, Fourth Clinical College of Nanjing Medical University, Nanjing, 210029, China.
Xiang-Long Tang *Department of Neuro-Psychiatric Institute, The Affiliated Brain Hospital With Nanjing Medical University, Nanjing, 210029, China. xltang0326@163.com.
Meng-Jie Zhao *Department of Neuro-Psychiatric Institute, The Affiliated Brain Hospital With Nanjing Medical University, Nanjing, 210029, China.
Yi-Ding ZhangDepartment of Neurosurgery, The Affiliated Brain Hospital With Nanjing Medical University, Fourth Clinical College of Nanjing Medical University, Nanjing, 210029, China.
Yong Xiao *Department of Neurosurgery, The Affiliated Brain Hospital With Nanjing Medical University, Fourth Clinical College of Nanjing Medical University, Nanjing, 210029, China.
Yu-Yang LiuDepartment of Neurosurgery, The Affiliated Brain Hospital With Nanjing Medical University, Fourth Clinical College of Nanjing Medical University, Nanjing, 210029, China.
Chun-Fa QianDepartment of Neurosurgery, The Affiliated Brain Hospital With Nanjing Medical University, Fourth Clinical College of Nanjing Medical University, Nanjing, 210029, China.
Yan-Dong XieDepartment of Neurosurgery, The Affiliated Brain Hospital With Nanjing Medical University, Fourth Clinical College of Nanjing Medical University, Nanjing, 210029, China.
Yong LiuDepartment of Neurosurgery, The Affiliated Brain Hospital With Nanjing Medical University, Fourth Clinical College of Nanjing Medical University, Nanjing, 210029, China.
Yuan-Jie ZouDepartment of Neurosurgery, The Affiliated Brain Hospital With Nanjing Medical University, Fourth Clinical College of Nanjing Medical University, Nanjing, 210029, China.
Kun YangDepartment of Neurosurgery, The Affiliated Brain Hospital With Nanjing Medical University, Fourth Clinical College of Nanjing Medical University, Nanjing, 210029, China. yk_nj@hotmail.com.
Hong-Yi LiuDepartment of Neurosurgery, The Affiliated Brain Hospital With Nanjing Medical University, Fourth Clinical College of Nanjing Medical University, Nanjing, 210029, China. njnkyylhy@163.com.
Nanjing Medical University · CNSecond Affiliated Hospital of Nanjing Medical University · CNNanjing Brain Hospital · CN

Funding

Jiangsu Province, the National Natural Science Foundation of China [81902535]Jiangsu Province, the National Natural Science Foundation of China [81972350]Postgraduate Research & Practice Innovation Program [NO. KYCX20_1419]the Clinical Medical Special Program of Science and Technology Project of Jiangsu Province [BE2019734]the Medical Research Foundation of Jiangsu Health Commission [H2019059]the Medical Science and Technology Development Foundation of Nanjing [YKK19088]the Science and Technology Development Foundation of Nanjing Medical University [2018095]
6 · The paper itself

Abstract

Although RNA interference (RNAi) therapy has emerged as a potential tool in cancer therapeutics, the application of RNAi to glioblastoma (GBM) remains a hurdle. Herein, to improve the therapeutic effect of RNAi on GBM, a cancer cell membrane (CCM)-disguised hypoxia-triggered RNAi nanomedicine was developed for short interfering RNA (siRNA) delivery to sensitize cells to chemotherapy and radiotherapy. Our synthesized CCM-disguised RNAi nanomedicine showed prolonged blood circulation, high BBB transcytosis and specific accumulation in GBM sites via homotypic recognition. Disruption and effective anti-GBM agents were triggered in the hypoxic region, leading to efficient tumor suppression by using phosphoglycerate kinase 1 (PGK1) silencing to enhance paclitaxel-induced chemotherapy and sensitize hypoxic GBM cells to ionizing radiation. In summary, a biomimetic intelligent RNAi nanomedicine has been developed for siRNA delivery to synergistically mediate a combined chemo/radiotherapy that presents immune-free and hypoxia-triggered properties with high survival rates for orthotopic GBM treatment.

Indexed as

Brain NeoplasmsGlioblastomaBiomimeticsCell Line, TumorHumansHypoxiaNanomedicineRNA InterferenceRNA, Small InterferingRNA, Small InterferingCancer cell membraneChemotherapyGlioblastomaHypoxia-triggeredRadiotherapysiRNA delivery

Identifiers

PMID37408007
PMCPMC10324258
OpenAlexW4383198714

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.